Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031096 | 0.98 | OPRM1 (0.58) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL18458358 | 0.88 | OPRM1 (0.56) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL22441511 | 0.88 | OPRM1 (0.59) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL2087707 | 0.87 | OPRM1 (0.59) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL2330456 | 0.87 | OPRM1 (0.56) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL1206633 | 0.87 | SIGMAR1 (0.59) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL2086022 | 0.87 | OPRM1 (0.56) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL5199646 | 0.87 | OPRM1 (0.55) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL14836350 | 0.87 | OPRM1 (0.55) | OPRM1TSHRCYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL14279621 | 0.84 | MC4R (0.59) | OPRM1CYP3A4HSD17B10SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| CN-102015683-B | The indole derivatives replaced | GRUNENTHAL GMBH (DE) | 2015-08-05 | — | — | CN | disclosed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2356101-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRM1 30/4885TSHR 2971/4885CYP3A4 89/4885 |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | ADORA2B, CCNB1, TYMS | OPRM1 1056/4885TSHR 370/4885CYP3A4 1682/4885 |
| US-20130116283-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRM1 30/4885TSHR 2971/4885CYP3A4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.